What is HC Wainwright’s Forecast for CRVS FY2024 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released on Thursday, January 2nd. HC Wainwright analyst S. Lee expects that the company will post earnings of ($0.41) per share for the year. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at $0.14 EPS.

Several other brokerages have also weighed in on CRVS. Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Finally, Oppenheimer lifted their price objective on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS opened at $5.83 on Monday. The business has a 50-day moving average of $7.67 and a 200 day moving average of $5.31. Corvus Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $10.00. The firm has a market cap of $374.62 million, a P/E ratio of -6.27 and a beta of 1.07.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Samlyn Capital LLC grew its holdings in Corvus Pharmaceuticals by 160.7% during the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after buying an additional 3,774,658 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $10,855,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Corvus Pharmaceuticals by 64.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock valued at $724,000 after buying an additional 53,809 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at about $74,000. Finally, State Street Corp boosted its position in shares of Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after acquiring an additional 57,943 shares during the last quarter. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.